Ikuo Yamamiya

409 total citations
22 papers, 304 citations indexed

About

Ikuo Yamamiya is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Ikuo Yamamiya has authored 22 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Oncology and 5 papers in Hematology. Recurrent topics in Ikuo Yamamiya's work include Fibroblast Growth Factor Research (10 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ikuo Yamamiya is often cited by papers focused on Fibroblast Growth Factor Research (10 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ikuo Yamamiya collaborates with scholars based in Japan, United States and United Kingdom. Ikuo Yamamiya's co-authors include Ken‐ichi Yamada, Hideo Utsumi, Karim A. Benhadji, Hendrik‐Tobias Arkenau, Yi He, Lipika Goyal, Rastislav Bahleda, Ben Tran, Ignacio Matos and Funda Meric‐Bernstam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Free Radical Biology and Medicine.

In The Last Decade

Ikuo Yamamiya

21 papers receiving 294 citations

Peers

Countries citing papers authored by Ikuo Yamamiya

Since Specialization

Citations

This map shows the geographic impact of Ikuo Yamamiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ikuo Yamamiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ikuo Yamamiya more than expected).

Fields of papers citing papers by Ikuo Yamamiya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ikuo Yamamiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ikuo Yamamiya. The network helps show where Ikuo Yamamiya may publish in the future.

Co-authorship network of co-authors of Ikuo Yamamiya

This figure shows the co-authorship network connecting the top 25 collaborators of Ikuo Yamamiya. A scholar is included among the top collaborators of Ikuo Yamamiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ikuo Yamamiya. Ikuo Yamamiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib 2024 ·Clinical and Translational Science ·Amanda Long, Ikuo Yamamiya, (unknown), (unknown), (unknown), (unknown), Volker Wacheck, Ling Gao	0
2	Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use 2023 ·ACS Medicinal Chemistry Letters ·Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, (unknown), Hideki Kazuno, Satoshi Yamashita, (unknown), Yoshihiro Shibata, Ikuo Yamamiya, (unknown), Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, (unknown), Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, Takeshi Sagara	16
3	Evaluation of the Cytochrome P450 3A and P‐glycoprotein Drug‐Drug Interaction Potential of Futibatinib 2023 ·Clinical Pharmacology in Drug Development ·Ikuo Yamamiya, (unknown), Toru Takenaka, Daryl Sonnichsen, (unknown), Yaohua He, Karim A. Benhadji, Ling Gao	6
4	Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants 2023 ·Clinical Pharmacology in Drug Development ·Ikuo Yamamiya, (unknown), (unknown), Daryl Sonnichsen, (unknown), Yaohua He, Karim A. Benhadji	8
5	A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib 2023 ·Clinical and Translational Science ·Ling Gao, Ikuo Yamamiya, Mark V. Pinti, (unknown), Thomas Marbury, (unknown), Lukas Makris, (unknown), Volker Wacheck	3
6	A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN -Inactivating Mutations 2022 ·Future Oncology ·Jordi Rodón, Pauline Funchain, Theodore W. Laetsch, Hendrik‐Tobias Arkenau, (unknown), Christian F. Singer, Yonina R. Murciano‐Goroff, Sant P. Chawla, (unknown), Ikuo Yamamiya, Mei Liu, Abdel‐Baset Halim, Karim A. Benhadji, Osamu Takahashi, Suzette Delaloge	12
7	TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress 2022 ·Communications Biology ·Hiroyuki Ueno, (unknown), (unknown), Sayaka Tsukioka, Takamasa Suzuki, (unknown), Yoshio Ogino, Khoon Tee Chong, Tatsuya Suzuki, Shingo Tsuji, (unknown), Ikuo Yamamiya, (unknown), Satoshi Ito, (unknown), (unknown), Nozomu Tanaka, (unknown)	3
8	Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double‐Blind, QT/QTc, Phase 1 Study in Healthy Subjects 2022 ·Clinical Pharmacology in Drug Development ·Ikuo Yamamiya, (unknown), Daryl Sonnichsen, (unknown), Yaohua He, Karim A. Benhadji	3
9	A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment 2021 ·Cancer Chemotherapy and Pharmacology ·Muhammad Wasif Saif, Carlos Becerra, Marwan Fakih, Weijing Sun, Lazar Popović, Smitha Krishnamurthi, Thomas J. George, Michelle A. Rudek, Dale R. Shepard, (unknown), Vladimír Šrámek, Bojan Zarić, Ikuo Yamamiya, Karim A. Benhadji, K Hamada, Yaohua He, Lee S. Rosen	6
10	52P Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) 2021 ·Annals of Oncology ·Antoine Hollebecque, John Bridgewater, Funda Meric‐Bernstam, Lipika Goyal, H-T. Arkenau, Ikuo Yamamiya, Fumiya Yamashita, (unknown), Volker Wacheck, Toshihiko Doi	3
11	First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT). 2021 ·Journal of Clinical Oncology ·Johann S. de Bono, Natalie Cook, Evan Y. Yu, Primo N. Lara, Judy S. Wang, (unknown), Ikuo Yamamiya, Ping Gao, (unknown), Dana E. Rathkopf	8
12	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations 2021 ·Investigational New Drugs ·Sarina A. Piha‐Paul, Analía Azaro, (unknown), Do‐Youn Oh, Matthew D. Galsky, Sumanta K. Pal, K Hamada, Yaohua He, Ikuo Yamamiya, Karim A. Benhadji, Antoine Hollebecque	6
13	Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors 2020 ·Annals of Oncology ·Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, Ben Tran, Yi He, Ikuo Yamamiya, Karim A. Benhadji, Ignacio Matos, Hendrik‐Tobias Arkenau	107
14	Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers 2018 ·Brain and Development ·Eri Takeshita, Hirofumi Komaki, Hisateru Tachimori, (unknown), Ikuo Yamamiya, Yuko Shimizu‐Motohashi, Akihiko Ishiyama, Takashi Saito, Eiji Nakagawa, Kenji Sugai, Masayuki Sasaki	17
15	A Phase I, single- and repeated-dose study of TAS-205, a novel inhibitor of hematopoietic prostaglandin D synthase, in patients with Duchenne muscular dystrophy 2017 ·Neuromuscular Disorders ·Hirofumi Komaki, Eri Takeshita, (unknown), Akihiko Ishiyama, Masayuki Sasaki, (unknown), Ikuo Yamamiya, Norio Yamada, (unknown)	3
16	Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity 2014 ·Drug Metabolism and Disposition ·Ikuo Yamamiya, Kunihiro Yoshisue, Yuji Ishii, Hideyuki Yamada, Masato Chiba	11
17	Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys 2014 ·Journal of Pharmacy and Pharmacology ·Ikuo Yamamiya, Kunihiro Yoshisue, Yuji Ishii, Hideyuki Yamada, (unknown)	4
18	Enantioselectivity in the cytochrome P450‐dependent conversion of tegafur to 5‐fluorouracil in human liver microsomes 2013 ·Pharmacology Research & Perspectives ·Ikuo Yamamiya, Kunihiro Yoshisue, Yuji Ishii, Hideyuki Yamada, Ken‐ichiro Yoshida	3
19	Formation Pathways of γ-Butyrolactone from the Furan Ring of Tegafur during Its Conversion to 5-Fluorouracil 2010 ·Drug Metabolism and Disposition ·Ikuo Yamamiya, Kunihiro Yoshisue, Eiji Matsushima, Sekio Nagayama	5
20	In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue 2006 ·Free Radical Biology and Medicine ·Ken‐ichi Yamada, Ikuo Yamamiya, Hideo Utsumi	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact